ClinicaliQ Trial Snapshot
- A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes — Recruiting • Phase III • Diabetes / Metabolic • NCT04786262.
- What is being tested: VX-880 is an investigational infusion therapy being evaluated for safety, tolerability, and efficacy in treating Type 1 diabetes, specifically targeting patients with impaired awareness of hypoglycaemia and severe hypoglycaemic episodes.
- Patient eligibility overview: The trial focuses on Type 1 diabetes patients with impaired awareness of hypoglycaemia (IAH) and a history of severe hypoglycaemic events—representing a high-risk subset of the T1D population with inadequate glycaemic control despite current therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Eligibility Snapshot
- Key Inclusion Criteria: * Clinical history of T1D with > 5 years of duration of insulin dependence * At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment * Stable diabetic treatment * Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.